AbbVie Inc. Files 8-K Report
Ticker: ABBV · Form: 8-K · Filed: Feb 5, 2025 · CIK: 1551152
| Field | Detail |
|---|---|
| Company | Abbvie Inc. (ABBV) |
| Form Type | 8-K |
| Filed Date | Feb 5, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01, $3.0 billion, $5.0 billion, $8.0 billion |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k
Related Tickers: ABBV
TL;DR
AbbVie filed a routine 8-K, no major news.
AI Summary
On January 30, 2025, AbbVie Inc. filed an 8-K report detailing "Other Events." The filing does not contain specific financial transactions or material events beyond routine reporting requirements, indicating no significant new developments at this time.
Why It Matters
This filing serves as a routine update for investors, confirming no major new events or disclosures from AbbVie Inc. as of January 30, 2025.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report for 'Other Events' and does not disclose any new material risks or significant financial changes.
Key Players & Entities
- AbbVie Inc. (company) — Filer of the 8-K report
- January 30, 2025 (date) — Date of the earliest event reported
- 001-35565 (other) — SEC File Number for AbbVie Inc.
FAQ
What is the primary purpose of this 8-K filing by AbbVie Inc.?
The primary purpose of this 8-K filing is to report on 'Other Events' as of January 30, 2025.
What is the SEC file number for AbbVie Inc.?
The SEC file number for AbbVie Inc. is 001-35565.
On what date was the earliest event reported in this filing?
The earliest event reported in this filing was on January 30, 2025.
What is the standard industrial classification for AbbVie Inc.?
The standard industrial classification for AbbVie Inc. is 'PHARMACEUTICAL PREPARATIONS [2834]'.
What is the state of incorporation for AbbVie Inc.?
AbbVie Inc. is incorporated in Delaware.
Filing Stats: 529 words · 2 min read · ~2 pages · Grade level 10.2 · Accepted 2025-02-05 16:15:17
Key Financial Figures
- $0.01 — e on which registered Common Stock, $0.01 Par Value ABBV New York Stock Excha
- $3.0 billion — ured revolving credit facility of up to $3.0 billion which matures on January 30, 2030. This
- $5.0 billion — n the Effective Date. AbbVie's existing $5.0 billion revolver maturing in March 2028 remains
- $8.0 billion — to revolving credit facilities totaling $8.0 billion in the aggregate. SIGNATURE Pursuan
Filing Documents
- tm255474d1_8k.htm (8-K) — 40KB
- 0001104659-25-009673.txt ( ) — 288KB
- abbv-20250130.xsd (EX-101.SCH) — 4KB
- abbv-20250130_def.xml (EX-101.DEF) — 30KB
- abbv-20250130_lab.xml (EX-101.LAB) — 40KB
- abbv-20250130_pre.xml (EX-101.PRE) — 28KB
- tm255474d1_8k_htm.xml (XML) — 11KB
01 Other
Item 8.01 Other Events. Revolving Credit Agreement On January 30, 2025 (the "Effective Date"), AbbVie Inc. ("AbbVie") entered into a revolving credit agreement (the "Revolving Credit Agreement") among AbbVie, as borrower, the lenders and other parties party thereto and JPMorgan Chase Bank, N.A., as administrative agent. The Revolving Credit Agreement establishes an unsecured revolving credit facility of up to $3.0 billion which matures on January 30, 2030. This facility enables AbbVie to borrow funds on an unsecured basis at variable interest rates and contains various covenants. AbbVie had no borrowings outstanding under the Revolving Credit Agreement on the Effective Date. AbbVie's existing $5.0 billion revolver maturing in March 2028 remains in effect, such that as of the Effective Date AbbVie has access to revolving credit facilities totaling $8.0 billion in the aggregate. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ABBVIE INC. By: /s/ Scott T. Reents Date: February 5, 2025 Name: Scott T. Reents Title: Executive Vice President, Chief Financial Officer